OBJECTIVES: The purpose of this study was to investigate whether mechanisms of azole resistance in Candida albicans contribute to reduced micafungin activity in vitro. METHODS: MICs were determined for a collection of strains with well-characterized mechanisms of azole resistance obtained from systemic, oral and vaginal infections. This collection of strains includes those with resistance-associated phenotypes. All known molecular mechanisms of azole resistance are included in this set of isolates (alone or in combination). Micafungin activity was further investigated for a subset of isolates by agar dilution. RESULTS: There was no correlation between any of the azole resistance mechanisms or resistance phenotypes and micafungin activity as determined by MIC, even in isolates with cross-resistance to multiple azole drugs. Overexpression of the ABC transporter CDR2 has been suggested to contribute to reduced echinocandin activity in agar dilution studies. By broth microdilution, there was no difference in MIC between the pump overexpressors and the collection as a whole. However, azole-resistant isolates from matched strains exhibited a small increase in their micafungin MICs relative to their susceptible controls. By agar dilution analysis, multiple CDR2-overexpressing strains exhibited reduced growth in the presence of micafungin relative to the laboratory strain SC5314. CONCLUSIONS: Azole resistance mechanisms do not contribute to increased micafungin MIC as determined by broth microdilution. However, within sets of matched isolates, strains overexpressing CDR2 had a slight increase in micafungin MIC. Changes in micafungin susceptibility are associated with CDR2 overexpression in agar dilution tests.
OBJECTIVES: The purpose of this study was to investigate whether mechanisms of azole resistance in Candida albicans contribute to reduced micafungin activity in vitro. METHODS: MICs were determined for a collection of strains with well-characterized mechanisms of azole resistance obtained from systemic, oral and vaginal infections. This collection of strains includes those with resistance-associated phenotypes. All known molecular mechanisms of azole resistance are included in this set of isolates (alone or in combination). Micafungin activity was further investigated for a subset of isolates by agar dilution. RESULTS: There was no correlation between any of the azole resistance mechanisms or resistance phenotypes and micafungin activity as determined by MIC, even in isolates with cross-resistance to multiple azole drugs. Overexpression of the ABC transporter CDR2 has been suggested to contribute to reduced echinocandin activity in agar dilution studies. By broth microdilution, there was no difference in MIC between the pump overexpressors and the collection as a whole. However, azole-resistant isolates from matched strains exhibited a small increase in their micafungin MICs relative to their susceptible controls. By agar dilution analysis, multiple CDR2-overexpressing strains exhibited reduced growth in the presence of micafungin relative to the laboratory strain SC5314. CONCLUSIONS:Azole resistance mechanisms do not contribute to increased micafungin MIC as determined by broth microdilution. However, within sets of matched isolates, strains overexpressing CDR2 had a slight increase in micafungin MIC. Changes in micafungin susceptibility are associated with CDR2 overexpression in agar dilution tests.
Authors: S Park; R Kelly; J Nielsen Kahn; J Robles; M-J Hsu; E Register; W Li; V Vyas; H Fan; G Abruzzo; A Flattery; C Gill; G Chrebet; S A Parent; M Kurtz; H Teppler; C M Douglas; D S Perlin Journal: Antimicrob Agents Chemother Date: 2005-08 Impact factor: 5.191
Authors: J Hiemenz; P Cagnoni; D Simpson; S Devine; N Chao; J Keirns; W Lau; D Facklam; D Buell Journal: Antimicrob Agents Chemother Date: 2005-04 Impact factor: 5.191
Authors: K Niimi; K Maki; F Ikeda; A R Holmes; E Lamping; M Niimi; B C Monk; R D Cannon Journal: Antimicrob Agents Chemother Date: 2006-04 Impact factor: 5.191
Authors: David A Stevens; Theodore C White; David S Perlin; Claude P Selitrennikoff Journal: Diagn Microbiol Infect Dis Date: 2005-03 Impact factor: 2.803
Authors: N T E de Wet; A J Bester; J J Viljoen; F Filho; J M Suleiman; E Ticona; E A Llanos; C Fisco; W Lau; D Buell Journal: Aliment Pharmacol Ther Date: 2005-04-01 Impact factor: 8.171
Authors: Jo-Anne H van Burik; Voravit Ratanatharathorn; Daniel E Stepan; Carole B Miller; Jeffrey H Lipton; David H Vesole; Nancy Bunin; Donna A Wall; John W Hiemenz; Yoichi Satoi; Jeanette M Lee; Thomas J Walsh Journal: Clin Infect Dis Date: 2004-10-27 Impact factor: 9.079
Authors: Seong Hyun Jeong; Dae Young Kim; Jun Ho Jang; Yeung-Chul Mun; Chul Won Choi; Sung-Hyun Kim; Jin Seok Kim; Joon Seong Park Journal: Ann Hematol Date: 2015-11-24 Impact factor: 3.673